Documentation

Press release

Datesort ascending Press release
26/02/2018 Inventiva announces positive outcomes of biomarker study measuring intracellular GAGs in leukocytes from MPS VI patients
12/02/2018 Inventiva Full-Year 2017 Financial Information and Business Update
01/02/2018 Half-yearly review and termination of a liquidity contract with Oddo BHF. Implementation of a new liquidity contract with Kepler Cheuvreux
31/01/2018 Inventiva to present in vivo data with odiparcil at the 14th WORLDSymposium™
04/01/2018 Inventiva Announces Positive DSMB Review in Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor
03/01/2018 Inventiva Announces Enrollment of First Patient into Its Odiparcil Phase IIa Trial (iMProveS) for MPS VI
13/11/2017 Inventiva to Present at Two Upcoming Investor Conferences
17/10/2017 Inventiva’s Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor Completes Enrollment
26/09/2017 INVENTIVA: FIRST-HALF 2017 RESULTS
18/09/2017 Inventiva’s IVA337 Given Generic Name “Lanifibranor” by the World Health Organization (WHO)
05/09/2017 Inventiva announces exercise of option by Boehringer Ingelheim to jointly develop potential new treatments for idiopathic pulmonary fibrosis (IPF)
04/09/2017 Inventiva and AbbVie Extend Agreement to Discover New Potent Orally-Available Small Molecule RORγ Inverse Agonist Drug Candidates
29/08/2017 Inventiva’s Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the European Medicines Agency
10/08/2017 Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the FDA
27/07/2017 Inventiva to Present New Data on IVA337 at the 15th International Workshop on Scleroderma Research in Pittsburgh, USA
29/06/2017 Inventiva Announces New Compelling Data on Odiparcil/IVA336 to be Presented at MPS Society National Conference
20/06/2017 Inventiva Announces Peer Review Publication of IVA337 Data in Pre-Clinical NASH Models
06/06/2017 Inventiva to Present at the Jefferies 2017 Global Healthcare Conference
31/05/2017 Résultat des votes de l’Assemblée Générale du 29 mai 2017 (Only in french)
30/05/2017 Dr Nanna Lüneborg, Principal of Novo Ventures, joins Inventiva’s Board

Pages